29In that regard, it is sufficient to state that, even if possible detriment to intra-Community trade was taken into consideration during the drawing up of Directive 89/105, its main purpose, according to its fifth recital, is to ensure transparency of pricing, including the manner in which it operates in individual cases and the criteria on which it is based, and to provide public access to pricing arrangements for all those involved in the market in medicinal products in the Member States. A barrier to intra-Community trade does not constitute a requirement for the application of that directive.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.